BLTENasdaqPharmaceutical PreparationsFiscal year ends December 31
BELITE BIO, INC
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$147.34+4.56 (+3.19%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2024 Ended Dec 31, 2024 | Mar 17, 2025 | Before market open | – | $-0.32 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 12, 2024 | After market close | – | $-0.25 | – |
Press releases
Announcements Belite Bio filed with the SEC
Uplisting to the Nasdaq Global Select Market
EX-99.1 to Form 6-K
Belite Bio Announces Submission of New Drug
EX-99.1 to Form 6-K
Bio Completes Rolling Submission of New Drug Application to
EX-99.1 to Form 6-K
Belite Bio Reports Unaudited First Quarter
EX-99.1 to Form 6-K
Belite Bio Initiates Rolling Submission of New
EX-99.1 to Form 6-K
Availability of Annual Report on Form 20-F
EX-99.1 to Form 6-K
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full
EX-99.1 to Form 6-K
Belite Bio Completes Enrollment in the DRAGON
EX-99.1 to Form 6-K
(Amounts in thousands of US Dollars, except
EX-99.1 to Form 6-K
Discussion and Analysis of Financial Condition and Results of Operations
EX-99.2 to Form 6-K
Belite Bio Announces Proposed Underwritten Public
EX-99.1 to Form 6-K
B E L I T E B I O / 1
EX-99.2 to Form 6-K
Belite Bio Reports Third Quarter 2025 Financial Results and Provides
EX-99.1 to Form 6-K
Belite Bio Announces Up to $275 Million Upsized Private Placement
EX-99.1 to Form 6-K
Belite Bio Reports Second Quarter 2025 Financial Results and Provides
EX-99.1 to Form 6-K
Registered Direct Offering of $15 Million
EX-99.1 to Form 6-K
Belite Bio Announces FDA Granting of Breakthrough
EX-99.1 to Form 6-K
Belite Bio Reports First Quarter 2025
EX-99.1 to Form 6-K
Results of 2025 General Meeting
EX-99.1 to Form 6-K
U.S. Securities and Exchange Commission
EX-99.1 to Form 6-K
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
EX-99.1 to Form 6-K
Our board of directors is soliciting proxies for the annual general
EX-99.2 to Form 6-K
Belite Bio Announces Availability of Annual
EX-99.1 to Form 6-K
Belite Bio Reports Fourth Quarter and Full Year
EX-99.1 to Form 6-K
Belite Bio Announces Registered Direct Offering of $15 Million
EX-99.1 to Form 6-K
Belite Bio Announces Appointment of Hendrik
EX-99.1 to Form 6-K
Belite Bio Reports Second Quarter 2024 Financial Results and Provides
EX-99.1 to Form 6-K
Belite Bio Reports First-Quarter 2024 Financial Results and Provides
EX-99.1 to Form 6-K
Belite Bio Announces $25 Million Registered
EX-99.1 to Form 6-K
PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
EX-99.1 to Form 6-K
Belite Bio Reports Fourth Quarter and Full Year
EX-99.1 to Form 6-K